12:00 AM
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Invega Sustenna regulatory update

Johnson & Johnson's Janssen Pharmaceuticals Inc. unit said FDA approved an sNDA to update the label of schizophrenia drug Invega Sustenna to include an extended dosing...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >